СУЛЬФАРГИН

Quick links

Choose a section

Quick links to important sections

Advertisements

СУЛЬФАРГИН

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of СУЛЬФАРГИН

Quick Facts

Property Description
Active ingredient Silver Sulfadiazine (Sulfadiazinum Argentum)
Form Ointment or Cream
Pharmacological class Topical Antimicrobial / Sulfonamide
Common use Infection prevention in burns and wounds
Origin Synthetic

1. What Type of Drug is СУЛЬФАРГИН? (Definition, Form, and Class)

СУЛЬФАРГИН is a topical chemotherapeutic agent, typically available as a 10 mg/g cream or ointment, used exclusively for external application on the skin. It is classified as an antimicrobial agent within the sulfonamide group, designed to control microbial contamination locally. Its active component is listed under the Anatomical Therapeutic Chemical (ATC) classification system as D06BA01, confirming its role as an external antimicrobial. Unlike systemic antibiotics, СУЛЬФАРГИН's action is localized, a feature clinically recognized for its targeted approach in surface-level wound management.

2. What is СУЛЬФАРГИН Composed Of? (Key Ingredients and Origin)

The core active ingredient in СУЛЬФАРГИН is Silver Sulfadiazine, a synthetic compound formed by chemically combining silver with a sulfa derivative. This dual-component structure is key to its efficacy, leveraging the antimicrobial properties of both the silver ions and the sulfonamide component. The product is manufactured as a specific, regulated entity within the broader category of Silver Sulfadiazine formulations. The unique structure is highly effective in wound care and is recognized as a standard topical anti-infective agent in managing burn injuries.

3. What is the General Therapeutic Goal of СУЛЬФАРГИН? (Primary Purpose)

The main therapeutic goal of СУЛЬФАРГИН is the prevention and treatment of microbial infection, particularly in patients with second- and third-degree burns and various skin ulcers. Its primary function is to maintain a controlled, low-microbe environment on the wound surface. By actively managing the microbial load locally, the drug helps prevent the serious complication of wound sepsis and supports the body's natural process of repair and recovery. It is utilized as an adjunct therapy and is not intended for use in treating underlying systemic infections.

Regulatory References

  1. StatPearls Review
Advertisements

What side effects are possible with СУЛЬФАРГИН?

Possible Side Effects and Safety Information

The official safety profile for Silver Sulfadiazine (СУЛЬФАРГИН) is categorized by the source and frequency of adverse reactions, distinguishing between common local effects and less frequent systemic risks.


Adverse Reaction Scope

The most common effects are generally local and dermatological, including pain, a burning sensation, itching (pruritus), a skin rash, and erythema (redness) at the application site. Less common effects include local allergic reactions.

The major safety concern is tied to the systemic absorption of the sulfadiazine component, particularly when applied to large wounds or for prolonged periods. This absorption can lead to rare but serious adverse reactions affecting various organ systems, including the blood and lymphatic system (e.g., transient leukopenia), renal (nephrotoxicity), and hepatic (hepatotoxicity) systems.


Population-Specific Safety Considerations

Specific populations have constraints based on regulatory documents. Silver Sulfadiazine is contraindicated in premature infants and neonates (under 2 months of age), and should be avoided in late-term pregnancy, due to the risk of kernicterus resulting from the sulfadiazine component. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency also face an elevated risk of hemolytic anemia.


Safety-Related Restrictions

Official prescribing information notes that systemic risks necessitate monitoring of blood cell counts and renal function when the product is applied to extensive burns. Furthermore, the product is not intended for application near the eyes, and its use on full-thickness burns requires prior surgical debridement of dead tissue.

Advertisements

Overdose and Emergency Response

An overdose of СУЛЬФАРГИН primarily concerns the potential for systemic absorption of the sulfonamide component, a risk associated with prolonged application or use over large body surface areas, such as extensive burns. Systemic exposure may lead to manifestations consistent with high sulfonamide levels, including the potential for crystalluria, where the drug precipitates in the renal tubules. Severe, officially documented outcomes include acute renal impairment or failure, methemoglobinemia, and serious hematological abnormalities or signs of hepatic damage.

The regulatory guidance requires users to seek immediate medical attention or contact emergency services upon the observation of any sign of systemic toxicity or suspected over-application. Cessation of medicinal product application is mandated immediately. No specific antidote is known for this overdose; therefore, management is officially documented as symptomatic and supportive treatment. This includes ensuring adequate fluid intake and continuous monitoring of urine output to assist with mitigating the risk of crystalluria. Further mandatory procedures involve the monitoring of renal function, hepatic function, and blood cell counts in a clinical setting. Patients with pre-existing renal or hepatic impairment are noted to carry an increased risk of severe systemic toxicity.

Advertisements

Therapeutic Uses of СУЛЬФАРГИН

What СУЛЬФАРГИН treats: main uses and benefits

СУЛЬФАРГИН is primarily used as an adjunct therapy for the prevention and management of microbial load in second-degree (deep partial-thickness) and third-degree (full-thickness) burns. This agent is also commonly applied in situations involving chronic, non-healing skin ulcers and leg ulcers. This medication is used to help manage and prevent infections in these severe skin conditions.

Its core therapeutic benefit is that it contributes to reducing the risk of developing a serious complication like burn wound sepsis. By controlling this bacterial presence, the medication may assist with managing symptom clusters that interfere with daily comfort, such as persistent microbial colonization. This supportive treatment is relevant in clinical settings marked by heightened physiological stress during the critical recovery phase, including inpatient care and pre-grafting preparation. The cream provides supportive relief when symptoms interfere with routine activities during difficult episodes of wound management.

“This application is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed.”

Quick Fact: Relief for Microbial Load
Primary Domain Topical Anti-Infective Prophylaxis
Conditions Severe burns, chronic skin ulcers, leg ulcers
Symptom Goal Contributes to reducing the risk of sepsis and easing the burden of persistent microbial contamination.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

СУЛЬФАРГИН (Silver Sulfadiazine) is a topical anti-infective primarily used as an adjunct for the prevention and treatment of wound infections in patients with second- and third-degree burns.


Who Can Use СУЛЬФАРГИН?

  • Patients, generally adults and children older than 2 months of age, who have sustained severe burns to reduce the risk of wound sepsis.
  • Individuals with other skin and wound infections, such as leg ulcers or pressure sores, as determined by a healthcare provider.

Who Cannot Use СУЛЬФАРГИН?

СУЛЬФАРГИН is contraindicated in several patient groups due to potential risks, including:

Patient Group Rationale for Contraindication
Infants Not recommended for premature infants or those under 2 months of age due to the risk of kernicterus (a form of brain damage) related to sulfonamide absorption.
Late-Term Pregnancy Women who are pregnant and near term should not use this drug, as absorbed sulfonamide may cause severe complications in the newborn.
Allergy Individuals with a known hypersensitivity to silver sulfadiazine, other sulfonamides (sulfa drugs), or any other ingredients in the cream.

Use with Caution

Your healthcare provider will use this medication with caution if you have a history of kidney disease, liver disease, or a genetic enzyme deficiency called glucose-6-phosphate dehydrogenase (G6PD) deficiency, as the absorption of the sulfonamide component could increase the risk of adverse effects.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation outlines interaction patterns for СУЛЬФАРГИН (Silver Sulfadiazine) based on the potential for systemic absorption of the sulfadiazine component or local interference by the silver component.


Documented Interaction Classifications

Interaction Classification Interacting Product(s) Official Constraint
Contraindicated Combination Methenamine Prohibited due to the risk of crystalluria formation.
Inactivation of Topical Agents Enzymatic Debriding Agents (e.g., Collagenase, Papain, Trypsin) Must not be applied concomitantly as the silver component can inactivate them.
Potentiation of Systemic Drug Effect Oral Hypoglycemic Agents, Phenytoin Increased effect may occur upon significant sulfadiazine absorption.
Increased Systemic Risk Cimetidine Associated with an increased incidence of leukopenia.

Population-Specific Interaction Note

Official labels indicate that the risk of systemic interactions and the accumulation of the sulfadiazine component may be higher in patients with hepatic or renal impairment. These official statements define the necessary vigilance when the product is used in these populations. The interaction profile strictly addresses combinations that are either prohibited or require monitoring due to the potential for altered drug effects.

Advertisements

Mechanism of Action

СУЛЬФАРГИН is a topical antimicrobial agent that acts through a dual mechanistic approach involving both the silver and sulfadiazine components.


Enzyme-Mediated Metabolic Disruption

This domain involves the action of the sulfadiazine moiety, a sulfonamide derivative. It acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase. This enzyme is essential for the bacterial synthesis of dihydrofolic acid, an early molecular step in the overall pathway for generating folic acid (vitamin B9). By blocking this critical step, СУЛЬФАРГИН ultimately prevents the formation of essential purines and pyrimidines, which are the building blocks of bacterial DNA and RNA. This modification of an early molecular step suppresses the metabolic sequence required for nucleic acid synthesis, resulting in the inhibition of bacterial cell proliferation.


️ Direct Cell Wall and Membrane Damage

This domain involves the action of the silver ions ( Ag^+) released from the compound. The released Ag^+ ions directly engage mechanisms that bind to the bacterial cell wall and cell membrane. This binding results in structural destabilization and increased permeability. Furthermore, silver ions penetrate the bacterial cell, binding to and disrupting vital intracellular components such as bacterial DNA and metabolic enzymes. This cascade modifies early molecular steps, leading to irreparable structural and functional cellular damage. The effects of the silver ions are concurrent with the metabolic inhibition induced by the sulfadiazine component.

Advertisements

Dosage and Administration Information

Official Administration Guidelines (Topical Use)

This medication, a topical cream, must be used strictly as directed by established guidelines to ensure continuous coverage of the affected area.

Administration Detail Official Instruction Summary
Route & Form Topical use only, applied as a cream.
Preparation The wound must be cleansed and debrided prior to the initial application of the cream.
Dosing Thickness Apply the cream to the affected areas in a layer of approximately 1/16 inch.
Frequency Apply once to twice daily (qDay–q12hr).
Reapplication The affected areas must be covered with the cream at all times. Reapply immediately to any area from which the cream has been removed, such as after patient activity or hydrotherapy.
Course Duration Treatment should continue until satisfactory healing has occurred or the burn site is ready for skin grafting.

Special Age-Group Rules

The use of this medicine is not recommended or is contraindicated in premature infants and newborn infants 2 months of age and younger. For children older than 2 months of age and adults, the dosing and regimen follow the general instructions above. Application should be performed under sterile conditions to minimize the risk of introducing pathogens into the wound area.

Note: If a scheduled application is missed, general guidelines emphasize reapplication as soon as the lapse is noticed, prioritizing continuous coverage of the wound.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for СУЛЬФАРГИН

Evidence for use in Infected Burn Wounds

Research was studied for the use of СУЛЬФАРГИН for research contexts involving infected burn wounds. The studies examined different types of research designs, including controlled clinical trials that was observed in patients over defined time intervals. Researchers investigated outcomes related to systemic or functional imbalance and monitored physiological strain. The findings describe patterns observed in the studies regarding how wound-related outcomes evolved in the observed populations. Evidence is limited regarding the long-term status of wounds studied in this way.

Evidence for use in Infected Skin Ulcers and Pressure Sores

The use of СУЛЬФАРГИН was evaluated in research exploring its role for research settings involving infected skin ulcers and pressure sores, which are conditions marked by functional limitations. The studies monitored outcomes reflecting daily functioning or activity level, alongside patient-reported outcomes describing perceived discomfort. Studies report how symptoms evolved in the observed populations when the medicine was observed in research exploring short-term symptom changes. Follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes.

Long-term Studies and Follow-up

Research was studied for the duration of treatment and subsequent follow-up. This research examined whether the observed changes persisted beyond the initial treatment period. However, long-term effects are not fully established. The evidence is limited regarding the extended-duration observations of patients. This means that long-term outcomes are not well characterized beyond the short-term periods tracked by the main studies.

Evidence in Special Populations

Some studies explored the application of СУЛЬФАРГИН in populations such as older adults, or those with certain comorbid conditions. However, data for certain groups remain insufficient. There is limited information for populations like children or those who are pregnant or breastfeeding, meaning subgroup findings are uncertain in these areas. The current results apply only to the populations studied and do not provide clear insight into the outcomes for every demographic.

What is still uncertain about СУЛЬФАРГИН

The available research contributes to the broader evidence landscape, but several areas of uncertainty remain. Evidence is limited in relation to long-term outcomes for all studied indications. Sample sizes were modest in many of the studies, and comparative evidence is lacking for some of the populations and outcomes monitored. The research does not determine whether an individual will respond similarly to the group patterns described in the studies.

Key Studies & References

  1. Label: SILVER SULFADIAZENE- silver sulfadiazine cream - DailyMed
  2. Pressure ulcer healing by daily topical sucralfate and silver sulfadiazine: A case report study - Brieflands
Advertisements

Frequently Asked Questions (FAQ)

Common questions about СУЛЬФАРГИН (FAQ)

Q: How quickly should I expect to see an effect from СУЛЬФАРГИН?

A: Studies on the active ingredient indicate that its antimicrobial action begins shortly after application in laboratory settings. However, the full therapeutic benefit is tied to the sustained application of the cream and the overall process of wound healing, which can take a period of time.

Q: What's the main difference between СУЛЬФАРГИН and other standard antiseptic creams?

A: According to official information, СУЛЬФАРГИН works via a dual mechanism. It combines the action of silver, which directly damages bacterial cells, with the sulfonamide component, which interrupts the bacteria's ability to produce necessary growth materials. This dual-action approach is distinct from the mechanisms of some other common topical antiseptic creams.

Q: Can СУЛЬФАРГИН be used on small cuts and scrapes, or is it too strong?

A: Official regulatory labeling primarily addresses its use for severe burns and skin ulcers. Any use outside of these approved indications should be discussed with a healthcare professional.

Q: Can СУЛЬФАРГИН cause a burning or stinging sensation when applied?

A: Yes, official safety information reports that common local adverse reactions at the application site include pain and a burning sensation. Any intense or unusual discomfort should be reported to a healthcare provider.

Q: Is it normal to see some skin discoloration after using СУЛЬФАРГИН for a while?

A: Yes, regulatory documents list skin discoloration as an infrequently occurring adverse event. This reaction is often described as a grayish or brownish-gray tint in the skin area where the cream has been applied.

Q: Does sun exposure become a problem while I'm using СУЛЬФАРГИН cream?

A: Yes, official warnings indicate that using this medication may make the treated area more sensitive to light, a condition known as photosensitivity. You should protect the affected areas from prolonged exposure to sunlight while using the cream.

Q: Can I apply other moisturizing lotions over СУЛЬФАРГИН after it dries?

A: Official administration guidelines emphasize the need to maintain a continuous, uninterrupted layer of the cream for consistent antimicrobial coverage. Applying other products on top is generally not addressed in the product labeling and may interfere with the continuous antimicrobial layer.

Q: Does СУЛЬФАРГИН interact with everyday vitamins or supplements?

A: Regulatory documents detail interactions with certain prescription medications like oral hypoglycemic agents, but they do not specifically address interactions with everyday vitamins or general dietary supplements. Official guidance advises patients to inform a healthcare provider of all products and supplements being used concurrently.

Q: What studies support the use of СУЛЬФАРГИН for deep second-degree burns?

A: Official labeling states that the drug is indicated for the prevention and treatment of wound sepsis in patients with second- and third-degree burns. This indication is based on clinical trials and established medical evidence for burn wound care.

Q: How long should a typical course of treatment with СУЛЬФАРГИН last?

A: The duration of treatment is not set for a fixed number of days or weeks. Official guidelines state that treatment should continue until satisfactory healing has occurred, or until the wound site is ready for a surgical procedure like skin grafting.

Q: Why is it recommended to remove dead tissue before applying СУЛЬФАРГИН?

A: The official administration instructions require that the wound be cleansed and debrided (meaning dead or damaged tissue is removed) prior to the initial application. This preparation ensures that the cream can make direct and effective contact with the viable wound bed.

Q: What kind of bandage should be used over the area treated with СУЛЬФАРГИН?

A: According to the product information, the treated areas can be left open or covered with a dressing, depending on the wound and patient needs. Dressings are not mandatory for the medication to work effectively.

Q: Is it possible for the bacteria to become resistant to СУЛЬФАРГИН over time?

A: Official warnings indicate that prolonged use may sometimes result in a superinfection. This refers to the overgrowth of new bacteria or fungi that may not be susceptible to the medication.

Q: I heard СУЛЬФАРГИН is used to prevent infection in skin grafts—is that true?

A: Official guidance states that the treatment is continued until the burn site is ready for skin grafting. Some regulatory summaries also include the prevention of bacterial colonization at skin graft donor sites as an approved use for the product.

Q: Does the cream need to be washed off before applying a new layer of СУЛЬФАРГИН?

A: The official instructions emphasize immediate reapplication if the cream is removed, such as after hydrotherapy, and do not explicitly mandate washing off the previous layer before reapplication.

Q: Can applying too much СУЛЬФАРГИН cause a problem?

A: The product label specifies the correct application thickness. Applying significantly more than the prescribed amount, particularly over a large surface area, can increase the amount of the sulfadiazine component absorbed into the body, which raises the potential for systemic adverse effects.

Q: Are there generic versions of СУЛЬФАРГИН available?

A: Yes, Silver Sulfadiazine cream, the active component of СУЛЬФАРГИН, is available in generic versions that have been approved by regulatory agencies, depending on regional availability and licensing.

Q: Can I use СУЛЬФАРГИН simultaneously with another topical medication?

A: Official documents warn that СУЛЬФАРГИН must not be applied at the same time as enzymatic debriding agents, such as collagenase or trypsin. This is because the silver component of the cream can inactivate these agents, stopping them from working.

Q: Is the silver in СУЛЬФАРГИН absorbed into the body?

A: Regulatory documents indicate that the sulfadiazine component is systemically absorbed and can reach substantial blood concentrations. While the silver component is part of the drug's mechanism, its absorption into the body is generally considered very limited.

Q: What's the difference in using the cream versus the powder form, if one exists?

A: Official regulatory labels classify and supply СУЛЬФАРГИН as a topical cream (1% strength). The labeling does not typically cover other dosage forms, such as a pure powder, for this specific product.

Q: Does СУЛЬФАРГИН protect against fungal infections as well as bacterial?

A: While in vitro tests show broad activity, the product information also includes a warning that fungal proliferation (overgrowth) may occur in the wound area.

Q: Does repeated, long-term use of СУЛЬФАРГИН pose any risk to general health?

A: The primary safety concern with long-term use, particularly on large areas, is the potential for systemic absorption of the sulfadiazine component. This absorption carries a rare risk of adverse effects impacting the blood, liver, or kidneys.

Q: Why does СУЛЬФАРГИН sometimes turn the wound bed a gray color?

A: The skin discoloration that may occur, often described as brownish-gray, is a known adverse effect. This coloration is believed to be associated with the presence of the silver component in the cream.

Q: What should I do if I accidentally swallow a small amount of СУЛЬФАРГИН?

A: СУЛЬФАРГИН is for external use only. If the cream is accidentally swallowed, a medical professional or poison control center should be contacted immediately for current guidance. Vomiting should not be induced unless a professional advises it.

Advertisements

How should СУЛЬФАРГИН be stored and disposed of?

Official Storage and Handling Requirements

Storage of СУЛЬФАРГИН (Silver Sulfadiazine) must strictly follow the conditions specified in the regulatory labeling to maintain product stability and safety. The mandatory storage requirements are defined by temperature constraints and protection rules.

Storage Component Required Regulatory Condition
Temperature Limit Store at a temperature not above 25 ºC
Handling Restriction Do not freeze the product
Expiration Do not use after the expiration date on the packaging

Child Safety and Disposal

The official labeling mandates that the product must be stored out of the sight and reach of children.

Disposal of unused or expired СУЛЬФАРГИН must be carried out according to local regulations for pharmaceutical waste. The product should not be disposed of via household trash or wastewater unless explicitly permitted by local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of СУЛЬФАРГИН found in:

A-Z Index: